Super antibacterial ‘Tygacil’ continues to monopolization, succeeding in defending patent
The domestic exclusive license of a Pfizer’s super antibacterial drug ‘Tygacil(tigecycline)’ is expected to be extended.
The substance patent of Tygacil was expired this May, but the company has blocked other generic companies using its valid composition patent expiring in 2026.
According to th...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
